Literature DB >> 17496164

Memantine inhibits ATP-dependent K+ conductances in dopamine neurons of the rat substantia nigra pars compacta.

Michela Giustizieri1, Maria Letizia Cucchiaroni, Ezia Guatteo, Giorgio Bernardi, Nicola B Mercuri, Nicola Berretta.   

Abstract

1-Amino-3,5-dimethyl-adamantane (memantine) is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist used in clinical practice to treat neurodegenerative disorders that could be associated with excitotoxic cell death. Because memantine reduces the loss of dopamine neurons of the substantia nigra pars compacta (SNc) in animal models of Parkinson's disease, we examined the effects of this drug on dopamine cells of the SNc. Besides inhibition of NMDA receptor-mediated currents, memantine (30 and 100 microM) increased the spontaneous firing rate of whole-cell recorded dopamine neurons in a midbrain slice preparation. Occasionally, a bursting activity was observed. These effects were independent from the block of NMDA receptors and were prevented in neurons dialyzed with a high concentration of ATP (10 mM). An increase in firing rate was also induced by the ATP-sensitive potassium (K(ATP)) channel antagonist tolbutamide (300 microM), and this increase occluded further effects of memantine. In addition, K(ATP) channel-mediated outward currents, induced by hypoxia, were inhibited by memantine (30 and 100 microM) in the presence of the NMDA receptor antagonist (5S, 10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801) (10 microM). An increase in the spontaneous firing rate by memantine was observed in dopamine neurons recorded with extracellular planar 8 x 8 multielectrodes in conditions of hypoglycemia. These results highlight K(ATP) channels as possible relevant targets of memantine effects in the brain. Moreover, in view of a proposed role of K(ATP) conductances in dopamine neuron degeneration, they suggest another mechanism of action underlying the protective role of memantine in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17496164     DOI: 10.1124/jpet.107.122036

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Firing properties and functional connectivity of substantia nigra pars compacta neurones recorded with a multi-electrode array in vitro.

Authors:  Nicola Berretta; Giorgio Bernardi; Nicola B Mercuri
Journal:  J Physiol       Date:  2010-03-29       Impact factor: 5.182

Review 2.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

3.  Effect of memantine on resting state default mode network activity in Alzheimer's disease.

Authors:  Marco Lorenzi; Alberto Beltramello; Nicola B Mercuri; Elisa Canu; Giada Zoccatelli; Francesca B Pizzini; Franco Alessandrini; Maria Cotelli; Sandra Rosini; Daniela Costardi; Carlo Caltagirone; Giovanni B Frisoni
Journal:  Drugs Aging       Date:  2011-03-01       Impact factor: 3.923

4.  Ca2+ influx through NMDA-gated channels activates ATP-sensitive K+ currents through a nitric oxide-cGMP pathway in subthalamic neurons.

Authors:  Ke-Zhong Shen; Steven W Johnson
Journal:  J Neurosci       Date:  2010-02-03       Impact factor: 6.167

5.  Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia.

Authors:  I V Litvinenko; M M Odinak; V I Mogil'naya; S V Perstnev
Journal:  Neurosci Behav Physiol       Date:  2010-02

6.  The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.

Authors:  Higo Fernando Santos Souza; Sandra Carla Rocha; Flávia Silva Damasceno; Ludmila Nakamura Rapado; Elisabeth Mieko Furusho Pral; Claudio Romero Farias Marinho; Ariel Mariano Silber
Journal:  PLoS Negl Trop Dis       Date:  2019-09-19

7.  Memantine has no effect on KATP channels in pancreatic β cells.

Authors:  Ryota Imai; Shingen Misaka; Shoichiro Horita; Shoko Yokota; Rie O'hashi; Yuko Maejima; Kenju Shimomura
Journal:  BMC Res Notes       Date:  2018-08-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.